title: Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer.
abstract: OBJECTIVE
  Preferences of women who had completed adjuvant chemotherapy for early breast cancer were compared with those of their partners by determining the smallest benefits they judged sufficient to make adjuvant chemotherapy worthwhile.
  
  
  METHODS
  Forty-six women and their partners were interviewed separately, 3-34 months after completing adjuvant chemotherapy. Preferences were elicited using four sets of validated, hypothetical trade-off scenarios about the possible benefits of adjuvant chemotherapy on survival times (5 and 15 years) and survival rates (65% and 85% at 5 years). Agreement within couples was assessed with the intraclass correlation coefficient (ICC). Associations between baseline characteristics, preferences, and agreement within couples were assessed with linear regression after normal score transformation.
  
  
  RESULTS
  The mean age of the women was 57 years and of their partners' was 60. Most couples were married (91%). Benefits of an extra 1 day or 0.1% were judged sufficient to make adjuvant chemotherapy worthwhile by 59-72% of women and 54-59% of partners. Agreement was exact in 35-41% of couples and approximate in 59-83%. Agreement was better for scenarios with a worse prognosis (ICC 0.67 and 0.35) than for scenarios with a better prognosis (ICC 0.13 and 0.05). Having dependent children was associated with partners requiring larger benefits but patients requiring smaller benefits to make adjuvant chemotherapy worthwhile (interaction P=0.001).
  
  
  CONCLUSIONS
  Patients' and partners' preferences for adjuvant chemotherapy differed and were influenced by considerations other than length and quality of life.
  
  
  CONCLUSIONS
  Clinicians who are aware of these differences can tailor discussions to ensure that all interested parties understand and agree on the goals and benefits of treatment.
authors.affiliation: NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia. vlatka@ctc.usyd.edu.au
authors.forename: Vlatka M
authors.initials: VM
authors.lastname: Duric
authors.forename: Phyllis N
authors.initials: PN
authors.lastname: Butow
authors.forename: Louise
authors.initials: L
authors.lastname: Sharpe
authors.forename: Stephane
authors.initials: S
authors.lastname: Heritier
authors.forename: Frances
authors.initials: F
authors.lastname: Boyle
authors.forename: Jane
authors.initials: J
authors.lastname: Beith
authors.forename: Nicholas R C
authors.initials: NR
authors.lastname: Wilcken
authors.forename: Alan S
authors.initials: AS
authors.lastname: Coates
authors.forename: R John
authors.initials: RJ
authors.lastname: Simes
authors.forename: Martin R
authors.initials: MR
authors.lastname: Stockler
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001294:Attitude to Health; D001943:Breast Neoplasms / Q000188:drug therapy / Q000523:psychology; D017024:Chemotherapy, Adjuvant / Q000379:methods / Q000523:psychology*; D002755:Choice Behavior; D003299:Cooperative Behavior; D034462:Dissent and Disputes; D005260:Female; D006801:Humans; D008017:Life Expectancy; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009517:New South Wales; D017697:Premenopause; D011379:Prognosis; D018454:Spouses / Q000523:psychology*; D011795:Surveys and Questionnaires; D015996:Survival Rate; D014930:Women / Q000523:psychology*
chemical_list: D000970:Antineoplastic Agents